![](/img/cover-not-exists.png)
A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03)
Rabab M. Gaafar, Veerle F. Surmont, Giorgio V. Scagliotti, Rob J. Van Klaveren, Demetris Papamichael, John J. Welch, Baktiar Hasan, Valter Torri, Jan P. van MeerbeeckVolume:
47
Year:
2011
Language:
english
Pages:
2341
DOI:
10.1016/j.ejca.2011.06.045
File:
PDF, 743 KB
english, 2011